Company Focus
Novartis
Latest Novartis News
Pharmaceutical
USA-based Light Horse Therapeutics has been established as a new small molecule therapeutics developer, with a $62 million Series A financing led by founding investor Versant Ventures and partnered with Novartis to identify and develop potentially advanced therapeutics. 10 January 2025
Related News
Insights
Company Spotlight
A clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience.
Latest News & Features of interest to Novartis
Pharmaceutical
Among significant news last week, the US Food and Drug Administration (FDA) required Agios Pharmaceuticals to amend the label for its hemolytic anemia drug Pyrukynd to reflect the risk of liver injury. Swiss ophthalmic drugs developer Oculis Holdings released positive Phase II results for its OCS-05. US drug developer Climb Bio entered into a licensing deal with China-based Mabworks Biotech on the latter’s monoclonal antibody CLYM116/MIL116. Also of note, US CRISPR gene editing company Intellia Therapeutics announced strategic plans which included cuts in programs and workforce. 12 January 2025
Biotechnology
Sage Therapeutics’ shares jumped over 45% to $8.09 in after-hours on Friday, after the company confirmed that biotech major Biogen has made a nonbinding proposal to acquire all of the outstanding shares of Sage not already owned by Biogen for $7.22 per share. 11 January 2025
Pharmaceutical
Artbio, a radiopharmaceutical company developing a new class of targeted alpha radioligand therapies (ARTs), has named Margaret Yu its chief medical officer (CMO). 10 January 2025
Biotechnology
US biopharma Vertex Pharmaceuticals has entered an exclusive collaboration and license agreement with China’s Zai Lab for the development and commercialization of Vertex’s povetacicept (pove) in mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore (the licensed territory). 10 January 2025
Biotechnology
US pharma giant Pfizer today announced positive top-line results from its pivotal Phase III CREST trial evaluating sasanlimab, an investigational anti-PD-1 monoclonal antibody (MAb), in combination with Bacillus Calmette-Guérin (BCG). 10 January 2025
Pharmaceutical
Chinese metabolic diseases specialist Hangzhou Sciwind Biosciences has announced details of a deal with Verdiva Bio for the global development and commercialization of a portfolio of therapies in territories outside of China and South Korea. 10 January 2025
Pharmaceutical
USA-based Light Horse Therapeutics has been established as a new small molecule therapeutics developer, with a $62 million Series A financing led by founding investor Versant Ventures and partnered with Novartis to identify and develop potentially advanced therapeutics. 10 January 2025
Biotechnology
German biotech CatalYm has appointed Scott Clarke as chief executive (CEO), noting that he brings over two decades of executive leadership experience in driving company growth, developing products, and shaping and executing transactions in the biopharmaceutical industry. 10 January 2025
Biotechnology
USA-based biotech builder Mountainfield Venture Partners and China’s Keymed Biosciences (HKEX: 02162) have joined forces to launch Timberlyne Therapeutics. 10 January 2025
Biosimilars
The US Food and Drug Administration approved 50 novel drugs in 2024, continuing to outpace its global regulatory peers. 10 January 2025
Latest In Brief for Novartis
Biotechnology
Netherlands-based Synaffix, a Lonza company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announced that it has licensed its ADC technology to Japan’s Mitsubishi Tanabe Pharma (MTPC). 9 January 2025
Latest Ones To Watch News
Sage Therapeutics’ shares jumped over 45% to $8.09 in after-hours on Friday, after the company confirmed that biotech major Biogen has made a nonbinding proposal to acquire all of the outstanding shares of Sage not already owned by Biogen for $7.22 per share. 11 January 2025
10 January 2025
8 January 2025
2 January 2025
27 December 2024
20 December 2024
19 December 2024
Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze